Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Non-Current Liabilities (2021 - 2024)

Aligos Therapeutics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $72.4 million for Q4 2024.

  • For Q4 2024, Other Non-Current Liabilities rose 162.24% year-over-year to $72.4 million; the TTM value through Dec 2024 reached $72.4 million, up 162.24%, while the annual FY2024 figure was $72.4 million, 162.24% up from the prior year.
  • Other Non-Current Liabilities reached $72.4 million in Q4 2024 per ALGS's latest filing, up from $11.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $72.4 million in Q4 2024 to a low of $133000.0 in Q4 2021.
  • Average Other Non-Current Liabilities over 4 years is $13.9 million, with a median of $267000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 50.19% in 2022, then surged 162.24% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $133000.0 in 2021, then changed by 0.0% to $133000.0 in 2022, then soared by 20648.87% to $27.6 million in 2023, then skyrocketed by 162.24% to $72.4 million in 2024.
  • Per Business Quant, the three most recent readings for ALGS's Other Non-Current Liabilities are $72.4 million (Q4 2024), $11.6 million (Q3 2024), and $11.5 million (Q2 2024).